Cloud Pharmaceuticals, Inc. Strengthens Management Team With Appointment Of Two C-Level Executives

RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2015 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, today announced the appointment of two C-level executives to its management team. Lyle Lohmeyer joins the company as its CFO and Don Van Dyke has been appointed COO.

"The appointments of Lyle and Don reflect Cloud Pharmaceuticals' strengthened position as a pioneer of cloud-based drug discovery," says Ed Addison, CEO, Cloud Pharmaceuticals. "With Lyle's oversight, we can pursue continued growth while maintaining fiscal responsibility. Don applies more than 20 years of business development experience in the life sciences industry, including time spent as a CEO of early-stage companies. Both offer expertise to help ensure that we deliver ongoing value to our customers, business partners, and investors."

Lyle Lohmeyer  
Chief Financial Officer

Lohmeyer has extensive experience as a financial executive with specific expertise in M&A, fundraising, debt control and administration, and operations management industries such as pharmaceutical services, clinical research, electronics, software, and manufacturing. At Cloud Pharmaceuticals, Lohmeyer's responsibilities include financial management, fundraising, and business development.

Previously, Lohmeyer held financial management positions with companies such as AAIPharma, Qualia Networks, Energy Conversion Systems Holdings, Abaco Mobile and NAVTEQ. He started his career with PricewaterhouseCoopers in Chicago. He holds a BSGM in accounting and finance from Purdue University's Krannert School of Management and a Masters of Management from Northwestern University's Kellogg School of Management. He is also a certified public accountant.

Don Van Dyke 
Chief Operating Officer

Van Dyke has been appointed to the role of chief operating officer. He was previously a consultant to the company and its director of marketing and business development. In his new role, Van Dyke is focusing on the business operations of the company. In addition, he is overseeing the company's marketing and business development efforts.

Van Dyke has held general management, business development, and sales and marketing positions throughout his career with companies such as American Hospital Supply, Eastman Kodak, and Millipore. He has built organizations from the ground up, beginning at startup Bio Image Corporation in various executive roles and ultimately CEO. He has held VP-level roles at Molecular Mining Corp. and INCOGEN and has advised more than a dozen startups and government agencies. Van Dyke has been an invited speaker at the Mason School of Business at the College of William and Mary and the Kenan-Flagler Business School at the University of North Carolina. He is a graduate of Duke University.

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners. For information visit www.cloudpharmaceuticals.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. 
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=107831

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cloud-pharmaceuticals-strengthens-management-team-with-appointment-of-two-c-level-executives-300129275.html

SOURCE Cloud Pharmaceuticals, Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.